Animal Carcinogenesis Core - Developmental Funds

发展基金有助于支持教师招聘过渡资金、试点项目资金以及在夏威夷大学癌症中心建立新的动物致癌核心。实现这一使命和长期目标有赖于招聘具有临床、基础、行为和流行病学专业知识的最高素质的科学家的能力，这些科学家能够领导高影响力的研究人员发起的研究，加强夏威夷癌症联盟(HCC)成员之间的研究合作，并推进UCC的转化研究议程。在当前的赠款周期中，CCSG提供的资金有限，可用作发展基金，其中大部分资金用于战略招聘，包括2006年招聘米歇尔·卡伯恩博士，他现在是大学健康中心主任。CCSG发展基金被用来支持另外两个招聘--获得V基金会奖和两个R01奖助金的Iona Cheng博士和获得AICR奖助金的Unhee Lim博士。过渡性资金将提供临时工资支持，并为有前途的调查人员提供研究支持。试点赠款将有助于制定新的合作倡议。新提出的动物致癌核心将增加UHCC利用最先进的动物模型进行转化性癌症研究、小鼠肿瘤组织库和动物实验专家咨询的机会。CCSG发展基金最终将继续帮助UCC利用重要的机构和慈善支持，其中一部分已投资于向UCC教职员工提供试点资金和过渡性资金，其中许多已导致新的或续签R01或NCI批准的同等针对癌症的资金。协调小组和机构发展基金过去的成功反映了为确保适当使用而建立的健全领导和监督机制。

Developmental funds are instrumental in supporting faculty recruitment bridge funding, pilot project funding and the establishment of the new Animal Carcinogenesis Core at the University of Hawai'i Cancer Center (UHCC). Achieving the mission and long-term goals UHCC is dependent upon the ability to recruit the highest caliber scientists with clinical, basic, behavioral, epidemiological expertise who can lead high impact investigator initiated research, strengthen research collaborations among members of the Hawai'i Cancer Consortium (HCC), and advance the translational research agenda of UHCC. In the current grant cycle limited CCSG funds were available for use as developmental funds and a majority of the funds were used for strategic recruitments, including the recruitment of Dr. Michele Carbone in 2006, who is now the Director of UHCC. CCSG Developmental Funds were used to support 2 additional recruitments - Dr. Iona Cheng, who is the recipient of a V Foundation award and 2 R01 grants and Dr. Unhee Lim, who was awarded an AICR grant. Bridge funding will provide support for interim salaries and research support for promising investigators. Pilot grants will enable the development of new collaborative initiatives. The newly proposed Animal Carcinogenesis Core will enhance UHCC opportunities to utilize state-of-art animal models for translational cancer research, a murine tumor tissue bank, and expert consultation regarding animal experiments. CCSG developmental funds will ultimately continue to help UHCC leverage significant institutional and philanthropic support, a portion of which has been invested into providing pilot funding and bridge funding to UHCC faculty, many of which have led to new or renewal R01 or equivalent NCI-approved cancer-focused funding. The past success of the CCSG and institutional Developmental Funds reflects the sound leadership of and oversight mechanisms in place to ensure appropriate use.